Skip to main content

Conference Correspondent

Conference Correspondent, ASH 2016 - Chronic Lymphocytic Leukemia
Phase 1b Results of a Phase 1b/2 Study of Obinutuzumab, Ibrutinib, and Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
Read More
Conference Correspondent, ASH 2016 - Chronic Lymphocytic Leukemia
Changes in Clinical Stage Identify Different Response Categories Among Patients in iwCLL PR: Analysis of CLL Patients on the RESONATE Study
Read More
Conference Correspondent, ASH 2016 - Chronic Lymphocytic Leukemia
PD-1 Blockade with Pembrolizumab in Relapsed CLL Including Richter’s Transformation: An Updated Report from a Phase 2 Trial (MC1485)
Read More
Conference Correspondent, ASH 2016 - Chronic Lymphocytic Leukemia
Integrated and Long-Term Safety Analysis of Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Read More
Conference Correspondent, ASH 2016 - Chronic Lymphocytic Leukemia
Identification of Baseline Characteristics That Predict Good Outcome of alloHCT in Young CLL Patients - A Retrospective Analysis from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation
Read More
Conference Correspondent, ASH 2016 - Chronic Lymphocytic Leukemia
Preclinical Analyses Support Clinical Investigation of Combined Anti-CD19 CAR-T Cell, JCAR017 with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia
Read More
Conference Correspondent, ASH 2016 - Chronic Lymphocytic Leukemia
Long-Term Follow-Up of Chlorambucil plus Rituximab Combination as Frontline Therapy for Elderly and/or Unfit Patients with CLL, Including Risk Stratification
Read More
Conference Correspondent, ASH 2016 - Chronic Lymphocytic Leukemia
Management and Outcomes of Atrial Fibrillation in Patients Receiving Ibrutinib for Hematologic Malignancies at a Single Center
Read More
Conference Correspondent, ASH 2016 - Chronic Lymphocytic Leukemia
Initial Results of a Multicenter, Phase II Study of Ibrutinib plus FCR (iFCR) as Frontline Therapy for Younger CLL Patients
Read More
Conference Correspondent, ASH 2016 - Chronic Lymphocytic Leukemia
11q Deletion (del11q) Is Not a Prognostic Factor for Adverse Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Ibrutinib: Pooled Data from 3 Randomized Phase 3 Studies
Read More
Page 6 of 8
Results 51 - 60 of 79